Abstract 635P
Background
Cetuximab could mediate, independently from RAS mutation, an immunogenic tumor cell death and antitumor immune response. This trial explores the efficacy and safety of AVE, CET and IRI for the treatment of refractory MSS mCRC.
Methods
Chemo-refractory (+anti-EGFR refractory if RAS wt) MSS, mCRC patients (pts) were enrolled in 3 cohorts (A: RAS wt, B & C: RAS mut) and treated with CET (500 mg/m2/Q2W), IRI (150 mg/m2/Q2W) and AVE (10 mg/kg/Q2W). Primary endpoints were safety, overall response rate (ORR) (cohorts A-B) and 6 months progression-free survival rate (6m-PFSR) (cohort C). Secondary and exploratory endpoints included disease control rate (DCR), PFS, OS and immunoscore (IS) biomarker. Based on a Simon 2-stage design (α=0.1; β=0.2) for ORR (cohorts A: P0/P1=0.15/0.33 – B: P0/P1=0.09/0.25) and 6m-PFSR (cohort C: P0/P1=0.15/0.31), 10+18 (A); 13+15 (B) and 14+25 (C) pts were needed. At least 2+5 (A); 2+3 (B) and 3+6 (C) pts must reach ORR (A-B) or 6m-PFSR (C) for efficacy objectives. Immunofluorescence (CD3, CD8 densities) was performed on baseline metastasis biopsies to generate IS.
Results
57 pts (median 62 yrs, 73.7% male, 84.2% left-sided, 86.0% synchr. mCRC) were included and 55 pts treated. Any treatment-emergent adverse event (AE) grade >=3 occurred in 35 pts (63.6%; diarrhea in 11 pts, 20.0%). Immune-related AEs grade >=3 appeared in 2 pts (3.6%; 1 acute kidney injury, 1 cholangitis). Efficacy results are summarized.
Table: 635P
| Characteristics | Cohort A (n=28) | Cohort B (n=13) | Cohort C (n=14) |
| ORR, % (pts) | 21.4% (6/28) | 0.0% (0/13) | 0.0% (0/14) |
| DCR, % (pts) | 50.0% (14/28) | 61.5% (8/13) | 42.9% (6/14) |
| 6m-PFSR, % (pts) | 25.0% (7/28) | 38.5% (5/13) | 7.1% (1/14) |
| Median PFS, months (95%CI) | 3.6 (2.5-5.6) | 3.7 (2.7-6.4) | 2.8 (2.4-3.8) |
| Median OS, months (95%CI) | 11.4 (5.3-15.6) | 10.1 (6.0-22.8) | 6.8 (5.3-9.7) |
Independently of RAS mutation, high IS was associated with greater tumor shrinkage (OR=8.3, p<0.01), DCR (OR=8.0, p=0.05), PFS (median 7.1 vs 3.1 months; HR=0.29, p<0.01) and OS (median 12.9 vs 7.2 months; HR=0.62, p=0.19).
Conclusions
Despite good tolerability, AVETUXIRI trial did not reach its efficacy endpoint. IS could be a predictive biomarker for selecting patients with potential treatment benefits.
Clinical trial identification
NCT03608046.
Editorial acknowledgement
Legal entity responsible for the study
Institut Roi Albert II - Cliniques universitaires St-Luc.
Funding
Merck Serono.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
812P - Mental and socioeconomic burden in co-parents and children of patients with endometrial and cervical cancer: A Swedish population-based study
Presenter: Karin Sundström
Session: Poster session 11
814P - Clinical significance of isolated pulmonary recurrence in patients with endometrioid endometrial cancer who achieved complete remission after primary treatment
Presenter: Jigeun Yoo
Session: Poster session 11
815P - Clinical outcome of metastatic endometrial carcinoma patients treated with chemotherapy: ENDOVIE, a GINECO national observational cohort study
Presenter: Jerome Alexandre
Session: Poster session 11
816P - Laparoscopic versus open-surgery in FIGO stage II endometrioid endometrium cancers: Is there a prognostic effect?
Presenter: Alain Zeimet
Session: Poster session 11
817P - A systematic review of recruitment of ethnic minorities to RCTs of systemic anti-cancer therapies in gynaecological cancers
Presenter: Luke Steventon
Session: Poster session 11